Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Testosterone cypionate - Pfizer

Drug Profile

Testosterone cypionate - Pfizer

Alternative Names: Andro-Cyp-100; Andro-Cyp-200; Andronaq-LA; Andronate; D-Tes 100; depAndro 100; depAndro 200; Depo; Depo-Testosterone; Depotest; Depotest 100; Depotest 200; Depovirin; Dura-Testosterone; Duratest; Duratest-100; Malogen Cyp; Man-Agin; Meditest; Pertestis; Shotest; T-Cypionate; Testa-C; Testadiate-Depo; Testaspan; Testergon; Testex Leo Prolongatum; Testodrin; Testoject; Testoject-100 LA; Testosterone cyclopentanepropionate; Testosterone cypionate; Testred Cypionate 200

Latest Information Update: 15 Jul 2015

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Class Anabolic steroids; Androstenols; Hormonal replacements; Small molecules; Testosterone congeners
  • Mechanism of Action Testosterone agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Andropause; Breast cancer; Breast disorders; Delayed puberty; Eunuchoidism; Hypogonadism; Oligospermia; Osteoporosis

Most Recent Events

  • 10 Jan 2019 Pfizer plans a phase I bioequivalence trial for Hypogonadism (In volunteers) in USA, in January 2019 (NCT03792477)
  • 24 Jun 2018 Biomarkers information updated
  • 01 Jul 2014 Forest Laboratories has been acquired by Actavis Inc
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top